Each of the following actors are typically engaged in the Al development life cycle EXCEPT?

• A. Legal and privacy governance experts.
• B. Government regulators.
• C. Data architects.
• D. Socio-cultural and technical experts.

CASE STUDY
Please use the following answer the next question:
A mid-size US healthcare network has decided to develop an Al solution to detect a type of cancer that is most likely arise in adults. Specifically, the healthcare network intends to create a recognition algorithm that will perform an initial review of all imaging and then route records a radiologist for secondary review pursuant Agreed-upon criteria (e.g., a confidence score below a threshold).
To date, the healthcare network has taken the following steps: defined its Al ethical principles: conducted discovery to identify the intended uses and success criteria for the system: established an Al governance committee; assembled a broad, crossfunctional team with clear roles and responsibilities; and created policies and procedures to document standards, workflows, timelines and risk thresholds during the project.
The healthcare network intends to retain a cloud provider to host the solution and a consulting firm to help develop the algorithm using the healthcare network's existing data and de-identified data that is licensed from a large US clinical research partner.
The most significant risk from combining the healthcare network's existing data with the clinical research partner data is?

• A. Privacy risk.
• B. Security risk.
• C. Reputational risk.
• D. Operational risk.

Scenario:
A European AI technology company was found to be non-compliant with certain provisions of the EU AI Act. The regulator is considering penalties under the enforcement provisions of the regulation.
According to the EU AI Act, which of the following non-compliance examples could lead to fines of up to €15 million or 3% of annual worldwide turnover(whichever is higher)?

• A. In case of AI Act prohibitions
• B. In case of the supply of misleading information to notified bodies in reply to a request
• C. In case of breach of a provider's obligations for high-risk AI systems
• D. In case of a breach of AI Act prohibition by the Union institutions, bodies, offices and agencies

You are the chief privacy officer of a medical research company that would like to collect and use sensitive data about cancer patients, such as their names, addresses, race and ethnic origin, medical histories, insurance claims, pharmaceutical prescriptions, eating and drinking habits and physical activity.
The company will use this sensitive data to build an Al algorithm that will spot common attributes that will help predict if seemingly healthy people are more likely to get cancer. However, the company is unable to obtain consent from enough patients to sufficiently collect the minimum data to train its model.
Which of the following solutions would most efficiently balance privacy concerns with the lack of available data during the testing phase?

• A. Refocus the algorithm to patients without cancer.
• B. Utilize synthetic data to offset the lack of patient data.
• C. Extend the model to multi-modal ingestion with text and images.
• D. Deploy the current model and recalibrate it over time with more data.

What is the primary objective of continuous monitoring in the lifecycle of an AI tool?

• A. To ensure that the AI tool's algorithm evolves independently to adapt to new data without human intervention.
• B. To track and adjust the tool's performance in order to ensure that it meets its goals.
• C. To periodically upgrade the AI tool's computational resources to maintain processing efficiency.
• D. To restrict the AI tool from accessing external data sources to maintain data privacy.